2. Academic Validation
  3. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis

Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis

  • Cell. 2022 Apr 28;185(9):1521-1538.e18. doi: 10.1016/j.cell.2022.03.030.
Rongqing Pan 1,  Jeremy Ryan 2,  Deng Pan 3,  Kai W Wucherpfennig 3,  Anthony Letai 4
Affiliations

Affiliations

  • 1 Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA. Electronic address: rongqing_pan@dfci.harvard.edu.
  • 2 Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA.
  • 3 Harvard Medical School, Boston, MA 02215, USA; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
  • 4 Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA. Electronic address: anthony_letai@dfci.harvard.edu.
PMID: 35447071 DOI: 10.1016/j.cell.2022.03.030
Abstract

Interest in harnessing natural killer (NK) cells for Cancer Immunotherapy is rapidly growing. However, efficacy of NK cell-based immunotherapy remains limited in most trials. Strategies to augment the killing efficacy of NK cells are thus much needed. In the current study, we found that mitochondrial Apoptosis (mtApoptosis) pathway is essential for efficient NK killing, especially at physiologically relevant effector-to-target ratios. Furthermore, NK cells can prime Cancer cells for mtApoptosis and mitochondrial priming status affects cancer-cell susceptibility to NK-mediated killing. Interestingly, pre-activating NK cells confers on them resistance to BH3 mimetics. Combining BH3 mimetics with NK cells synergistically kills Cancer cells in vitro and suppresses tumor growth in vivo. The ideal BH3 mimetic to use in such an approach can be predicted by BH3 profiling. We herein report a rational and precision strategy to augment NK-based immunotherapy, which may be adaptable to T cell-based immunotherapies as well.

Keywords

BCL-2; BH3 mimetics; BH3 profiling; MCL-1; T cells; immunotherapy; mitochondrial apoptosis; natural killer; synergy; venetoclax.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z